You have no items in your cart.
Fitusiran Reduced Bleeding Regardless of Inhibitor Status

Monthly treatment with the investigational medication fitusiran can reduce bleeding in people with hemophilia A and B, with or without inhibitors, according to data from two Phase 3 clinical trials. “We are encouraged by the data from these initial Phase 3 studies demonstrating fitusiran’s potential as a new therapeutic option for people with hemophilia A or B, regardless of inhibitor status,” Dietmar Berger, MD, PhD, said in a press release. Berger is head of global…